Phathom Pharmaceuticals, Inc. (PHAT)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1783183 · fiscal year ends in Dec
Closing price $6.24 on 29 Oct 2026; 52-week range $5.72 to $18.08.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $274.9M
- Revenue growth
- 86.8%
- Net income, last twelve months
- -$83.0M
- Earnings per share
- -$1.03
- Gross margin
- 80.7%
- Operating margin
- -9.3%
- Net margin
- -30.2%
- Free cash flow
- -$21.0M
- Market value
- $506.8M
- Cash
- $184.6M
- Debt
- $165.5M
- Shares outstanding
- 81.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $175.1M | -$160.0M | -$221.2M | -$3.03 | -$167.0M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $55.3M | -$277.5M | -$334.3M | -$5.29 | -$266.9M | 10-K filed 6 Mar 2025 |
| FY2023 | 31 Dec 2023 | $682.0K | -$167.3M | -$201.6M | -$3.93 | -$139.2M | 10-K filed 7 Mar 2024 |
| FY2022 | 31 Dec 2022 | $0 | -$172.4M | -$197.7M | -$5.05 | -$147.6M | 10-K filed 7 Mar 2024 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $84.7M | -$13.9M | -$0.16 |
| Q2 FY2026 | 30 Jun 2026 | $74.3M | -$17.6M | -$0.21 |
| Q1 FY2026 | 31 Mar 2026 | $58.3M | -$30.4M | -$0.37 |
| Q4 FY2025 | 31 Dec 2025 | $57.6M | -$21.1M | -$0.29 |
| Q3 FY2025 | 30 Sep 2025 | $49.5M | -$30.0M | -$0.41 |
| Q2 FY2025 | 30 Jun 2025 | $39.5M | -$75.8M | -$1.05 |
| Q1 FY2025 | 31 Mar 2025 | $28.5M | -$94.3M | -$1.31 |
| Q4 FY2024 | 31 Dec 2024 | $29.7M | -$74.5M | -$1.05 |
Company events
The newest 8-K filings of 102 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 29 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 26 Oct 2026 | 8-K | Other events | 8.01 |
| 23 Oct 2026 | 8-K | Other events | 8.01 |
| 29 Sep 2026 | 8-K | Other events | 8.01 |
| 30 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Jun 2026 | 8-K | Other events | 8.01 |
| 21 May 2026 | 8-K | Shareholder vote | 5.07 |
| 30 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 8 Jan 2026 | 8-K | Other events | 8.01, 9.01 |
| 7 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Nov 2025 | 8-K | Other events | 8.01 |
Every filing
The newest filings with the SEC of 193 held.
| Filed | Form | Period |
|---|---|---|
| 29 Oct 2026 | 10-Q | 30 Sep 2026 |
| 29 Oct 2026 | 8-K | 29 Oct 2026 |
| 26 Oct 2026 | 8-K | 26 Oct 2026 |
| 23 Oct 2026 | 8-K | 23 Oct 2026 |
| 29 Sep 2026 | 8-K | 29 Sep 2026 |
| 30 Jul 2026 | 10-Q | 30 Jun 2026 |
| 30 Jul 2026 | 8-K | 30 Jul 2026 |
| 23 Jun 2026 | 8-K | 23 Jun 2026 |
| 21 May 2026 | 8-K | 19 May 2026 |
| 30 Apr 2026 | 10-Q | 31 Mar 2026 |
| 30 Apr 2026 | 8-K | 30 Apr 2026 |
| 7 Apr 2026 | DEFA14A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 3 Nov 2025 | Breedlove Robert Charles, Principal Accounting Officer | Sale outside a trading plan | 524 | $13.51 | $7.1K | 47,407 | 5 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 29 Jul 2026 | BlackRock, Inc. | 13G | 5.5% | 4.4M |
| 20 Jul 2026 | Millennium Management LLC | 13G amended | 4.2% | 3.4M |
| 12 Mar 2026 | Millennium Management LLC | 13G | 5.3% | 4.2M |
| 27 Jan 2026 | Integrated Core Strategies (US) LLC | 13G amended | 2.7% | 2.1M |
| 4 Nov 2025 | Frazier Life Sciences Public Fund, L.P. | 13D amended | 8.6% | 6.0M |
| 3 Nov 2025 | Integrated Core Strategies (US) LLC | 13G amended | 7.1% | 5.1M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 9.8M | -3.21% | 6.93 |
| 30 Sep 2026 | 10.1M | -0.47% | 7.36 |
| 15 Sep 2026 | 10.2M | -6.16% | 9.11 |
| 31 Aug 2026 | 10.8M | -8.07% | 11.01 |
| 14 Aug 2026 | 11.8M | -11.66% | 6.87 |
| 31 Jul 2026 | 13.3M | +9.95% | 8.7 |
| 15 Jul 2026 | 12.1M | +1.07% | 9 |
| 30 Jun 2026 | 12.0M | +7.44% | 11.67 |
Funds that hold it
From each fund's latest Form 13F.
193 funds held it at 30 Jun 2026: 76 added and 50 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 12,466,489 | $135.3M | 0 |
| Medicxi Ventures Management (Jersey) Ltd | 7,464,572 | $81.0M | 0 |
| BlackRock, Inc. | 4,525,129 | $49.1M | +463,133 |
| Invesco Ltd. | 4,029,731 | $43.7M | -292,329 |
| Carlyle Group Inc. | 3,496,808 | $37.9M | 0 |
| Millennium Management LLC | 3,375,834 | $36.6M | -647,075 |
| Vanguard Capital Management LLC | 2,656,944 | $28.8M | +73,308 |
| GW&K Investment Management, LLC | 2,166,838 | $23.5M | +745,729 |
| Franklin Resources Inc. | 1,970,828 | $21.4M | +976,324 |
| NEA Management Company, LLC | 1,960,169 | $21.3M | 0 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B